Key result
Carvedilol reversed cardiac hypertrophy and haemodynamic deficiencies in AKAP5 knockout mice by normalizing the activities of cardiac calcineurin and CaMKII.
Why the study?
Does carvedilol reverse cardiac insufficiency and hypertrophy in AKAP5 knockout mice?
Does carvedilol reverse cardiac insufficiency and hypertrophy in AKAP5 knockout mice?
Carvedilol reverses cardiac hypertrophy and dysfunction in AKAP5 knockout mice by normalizing calcineurin and CaMKII activities, highlighting a cardioprotective role for AKAP5.
Hypothesis-generating for carvedilol in AKAP5-related hypertrophy; human translation requires prospective validation.
AIMS: Cardiac β-adrenergic receptors (β-AR) are key regulators of cardiac haemodynamics and size. The scaffolding protein A-kinase anchoring protein 79/150 (AKAP5) is a key regulator of myocardial signalling by β-ARs. We examined the function of AKAP5 in regulating cardiac haemodynamics and size, and the role of β-ARs and Ca(2+)-regulated intracellular signalling pathways in this phenomenon. METHODS AND RESULTS: We used echocardiographic, histological, genetic, and biochemical methods to examine the effect of ablation of AKAP5 on cardiac haemodynamics, size, and signalling in mice. AKAP5(-/-) mice exhibited enhanced signs of cardiac dilatation and dysfunction that progressed with age. Infusions of isoprenaline worsened cardiac haemodynamics in wild-type (WT) mice only, but increased the ratio of heart-to-body weight equally in WT and in AKAP5(-/-) mice. Mechanistically, loss of AKAP5 was associated with enhanced activity of cardiac calmodulin kinase II (CaMKII) and calcineurin (CaN) as indexed by nuclear factor of activated T-cell-luciferase activity. Loss of AKAP5 interfered with the recycling of cardiac β1-ARs, which was mediated in part by CaN binding to AKAP5. Carvedilol reversed cardiac hypertrophy and haemodynamic deficiencies in AKAP5(-/-) mice by normalizing the activities of cardiac CaN and CaMKII. CONCLUSIONS: These findings identify a novel cardioprotective role for AKAP5 that is mediated by regulating the activities of cardiac CaN and CaMKII and highlight a significant role for cardiac β-ARs in this phenomenon.
No takes yet. Share an insight, caveat, or question.
Li et al. (2014) studied Cardiac insufficiency and hypertrophy. Carvedilol vs. Untreated AKAP5(-/-) mice / Wild-type mice was evaluated on Cardiac haemodynamics, size, and signalling activities (CaN and CaMKII). Carvedilol reversed cardiac hypertrophy and haemodynamic deficiencies in AKAP5 knockout mice by normalizing the activities of cardiac calcineurin and CaMKII.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: